China's CanSino Biologics Inc said on Wednesday that no serious blood clot cases had been reported so far in people who were injected with its Covid-19 vaccine Ad5-nCoV.

The announcement follows US federal health agencies' recommendation on Tuesday that the use of Johnson & Johnson's Covid-19 vaccine, which uses similar technology to CanSinoBIO's product, should be paused for at least a few days after six women younger than 50 developed rare blood clots after receiving the shot...